Drug Trial Radar · NCT04762758
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
350
Planned (sponsor's estimate)
Start
Mar 30, 2021
Primary completion
Apr 19, 2024
Study completion Apr 19, 2024
Sponsor
- Lead sponsor
- Pharnext S.C.A.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Worldwide Clinical Trials
- First posted
- Feb 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will consist of 2 periods: Double-blind Treatment and Open-Label Extension(OLE) Period. -Double-blind Treatment Period - This will be randomized, double-blind, placebo-controlled part of the study which will be conducted in parallel groups, ie,1 group receiving the active treatment (PXT3003) and the other group receiving placebo. Primary endpoint of the study will be assessed at Month 15. -Open-label Extension (OLE) Period - All subjects completing Double-blind Treatment Period will be given an opportunity to enter the OLE Period of the study and receive the active treatment (PXT3003). The duration of the OLE Period will be based on Sponsor discretion, ie, Sponsor intends to keep the study open until the study drug PXT3003 is commercially available. During this period, the long-term safety and efficacy of PXT3003 will be assessed as an exploratory objective. Double-blind Treatment Period Objectives: Primary: To evaluate the efficacy of treatment with PXT3003 (a fixed-dose combination of \[RS\]-baclofen, naltrexone hydrochloride \[HCl\], and D-sorbitol) compared to placebo in subjects with Charcot-Marie-Tooth disease type 1A (CMT1A). Secondary: To evaluate the safety and tolerability of PXT3003 treatment in subjects with CMT1A. Exploratory: To characterize the relationship between plasma biomarkers and response to PXT3003 treatment. OLE Period Objective: Exploratory: To evaluate the long-term safety and efficacy of PXT3003.
Conditions
- Charcot-Marie-Tooth Disease
Interventions
(RS)-baclofen, naltrexone hydrochloride and D-sorbitolDrug
oral fixed dose combination
PlaceboDrug
liquid oral solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- modified Overall Neuropathy Limitation Scale (mONLS)Time frame: From Baseline to Month 15
Locations
50 sites in 9 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
UCLA Department of Psychiatry and Biobehavioral Sciences
Los Angeles, California
UC Davis Health Department of Physical Medicine and Rehabilitation
Sacramento, California
Hospital for Special Care
New Britain, Connecticut
University of Florida Clinical Research Center
Gainesville, Florida
University of Miami Leonard M. Miller School of Medicine
Miami, Florida
Advent Health Medical Group Neurology Orlando
Orlando, Florida
University of Kansas Medical Center Research Institute
Fairway, Kansas
Massachusetts General Hospital Neuromuscular Diagnostic Center
Boston, Massachusetts
University of Minnesota Health
Minneapolis, Minnesota
MU Health Care Neurology and Sleep Disorders Clinic
Columbia, Missouri
Hackensack Meridian Health Hackensack University Medical Center
Hackensack, New Jersey
Colombia University Department of Neurology
New York, New York
UNC Department of Neurology Peripheral Neuropathy Center
Chapel Hill, North Carolina
Atrium Health Neurosciences Institute
Charlotte, North Carolina
The Ohio State University Wexner Medical Center
Columbus, Ohio
Oregon Neurology
Springfield, Oregon
National Neuromuscular Research Institute
Austin, Texas
Neurology Clinic at University of Washington Medical Center
Seattle, Washington
Providence St. Luke's Rehabilitation Medical Center
Spokane, Washington
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
Ottawa Hospital Research Institute- Neuromuscular Research Centre
Ottawa, Ontario, Canada
UHN Toronto General Hospital Krembil Neuroscience Centre
Toronto, Ontario, Canada
CIUSS de Saguenay-Lac-Saint-Jean Centre d'etudes Cliniques
Chicoutimi, Quebec, Canada
Montreal Neurological Institute and Hospital-Clinical Research Unit
Montreal, Quebec, Canada
CHU de Quebec-Universite Laval- Hopital Enfant-Jesus
Québec, Quebec, Canada
Rigshospitalet, University of Copenhagen Copenhagen Neuromuscular Center
Copenhagen, Denmark
Centre de Reference des Maladies Neuromusculaires AOC Service de Neurologie, CHU d'Angers
Angers, France
Centre de reference des maladies neuromusculaires AOC Hopital Pellegrin CHU de Bordeaux
Bordeaux, France
CHU de Lille Hôpital Salengro
Lille, France
Service de Neurologie et Maladies Neuromusculaires, CHU de Marseille - Hopital La Timone
Marseille, France
Association lnstitut de Myologie Hopital Pitie-Salpetriere Service de Neuro-Myologie
Paris, France
Centre d'investigation Clinique CHU de Strasbourg Hopital de Hautepierre
Strasbourg, France
University Hospital RWTH Aachen, Department of Neurology and Institute for Neuropathology
Aachen, Germany
University Medical Centre Goettingen, Dept. of Clinical Neurology
Göttingen, Germany
Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik Ludwig-Maximilians-Universität
München, Germany
University Hospital Muenster UKM Department of Neurology
Münster, Germany
Universitätsklinikum Tübingen Crona Kliniken Neuromuskuläres Zentrum
Tübingen, Germany
Hadassah Ein Kerem University Medical Center Department of Neurology
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.